Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.

  • 101 - 250


Last Funding Type
Series Unknown
Last Funding Money Raised
Biopharma,Biotechnology,Health Care,Life Science,Therapeutics
Founded date
Jan 1, 2003
Number Of Employee
101 - 250
Operating Status

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
Ambrx has raised a total of $135.44M in funding over 2 rounds. Their latest funding was raised on Aug 4, 2016 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 4, 2016 Series Unknown $45M 1 Detail
Apr 1, 2009 Series D $10M 1 Detail
Jul 5, 2006 Series C $52M 1 Detail
Jan 25, 2006 Series B $5M 1 Detail
Mar 21, 2005 Series A $23.44M 1 Detail


Number of Lead Investors
Number of Investors
Ambrx is funded by 2 investors. HOPU Investment Management Company and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
HOPU Investment Management Company Series Unknown
Versant Ventures Series D